No abstract
e22176 Background: The Institute of Advances in Medicine is a private referral center in Brazil that treats patients with advanced disease, often after failure to previous lines of treatments. Predictive response assays allow physicians to make better informed choices when establishing the therapeutic strategy for each patient. Methods: 48 patients (21 male; 27 female), 54.5 y old (33-80y) with advanced disease were submitted to molecular diagnostic investigation using paraffin-embedded tumor samples from Brazil, shipped to Caris Target Now-US in accordance with the Brazilian Federal Sanitary Agency regulations. We have considered the samples diversity, different tumor sites, tissue availability and technical conservation. Results: More than 1920 IHC, FISH or CISH, RT-PCR, RFLP, sequencing and mutational analysis by PCR were performed, with a list of drugs with Potential Clinical Benefit (PCB) or Potential Lack of Benefit (PLB) for the 48 primary tumors: 11 colorectal, 9 breast, 6 NSCLC, 22 other sites. Drugs were listed in the PCB column that were usual drugs in first and second line treatments for their cancer types. However, many patients were classified with PLB with drugs that they had used before and were not active. These data were analyzed for Performance Status, Previous Treatments actually given and current commercially available anticancer agents, such as chemotherapeutic and new molecular targeted agents to help the decision for future treatments. Conclusions: When the test was performed, patients had already been treated (and had had disease progression) with drugs that were listed as potentially lacking benefit. Time is ripen for testing tumors prior to beginning clinical treatment, since it may provide a better understanding of the tumor biology and the probable clinical response, making it possible to distinguish which therapeutic schedule is preferable. The present availability of reliable predictive assays for assessing tumor sensitiveness (or lack of it) to anticancer drugs makes it imperative to change guidelines. The ever growing health costs in the public health systems around the world may also benefit from such strategy since only drugs with a potential for response will be chosen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.